Gustaf Ulfhammer1, Arvid Edén1, Åsa Mellgren1,2, Dietmar Fuchs3, Henrik Zetterberg4,5,6,7, Lars Hagberg1, Staffan Nilsson8, Aylin Yilmaz1, Magnus Gisslén1. 1. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg. 2. Clinic of Infectious Diseases, South Älvsborg Hospital, Borås, Sweden. 3. Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria. 4. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg. 5. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 6. Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London. 7. UK Dementia Research Institute, London, UK. 8. Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden.
Abstract
OBJECTIVE: Low-grade immune activation is common in people living with HIV (PLHIV), despite long-term viral suppression by antiretroviral therapy (ART). The clinical significance of this activation remains unclear. The aim of this study was to examine residual intrathecal immune activation in relation to signs of neuronal injury and neurocognitive impairment in PLHIV who had been virally suppressed on ART for more than 10 years. DESIGN/ METHODS: Twenty neuroasymptomatic PLHIV on suppressive ART for a median of 13.2 years were retrospectively identified from the longitudinal prospective Gothenburg HIV cerebrospinal fluid (CSF) study. HIV-RNA, neopterin, and neurofilament light protein (NFL) levels were measured in paired plasma and CSF samples. Pretreatment samples were available for 14 patients. Cognitive function was assessed by CogState at follow-up. RESULTS: CSF neopterin decreased from a median (IQR) of 17.8 (10.6-29.7) to 6.1 (4.6-8.0) nmol/l during treatment (P < 0.001). In 11 out of 20 participants (55%), CSF neopterin levels were above the upper normal reference limit (5.8 nmol/l) at follow-up. Age-adjusted CSF NFL decreased to within-normal levels from a median of (IQR) 1179 (557-2707) to 415 (292-610) ng/l (P < 0.001). No significant correlations were found between CSF neopterin and CSF NFL or neurocognitive performance. CONCLUSION: Although CSF neopterin decreased significantly, more than 50% of the patients had CSF concentrations above the upper normal reference value despite more than 10 years of suppressive ART. We found no correlation between CSF neopterin, CSF NFL or neurocognitive performance at follow-up, indicating that low-grade immune activation during suppressive ART may be clinically benign.
OBJECTIVE: Low-grade immune activation is common in people living with HIV (PLHIV), despite long-term viral suppression by antiretroviral therapy (ART). The clinical significance of this activation remains unclear. The aim of this study was to examine residual intrathecal immune activation in relation to signs of neuronal injury and neurocognitive impairment in PLHIV who had been virally suppressed on ART for more than 10 years. DESIGN/ METHODS: Twenty neuroasymptomatic PLHIV on suppressive ART for a median of 13.2 years were retrospectively identified from the longitudinal prospective Gothenburg HIV cerebrospinal fluid (CSF) study. HIV-RNA, neopterin, and neurofilament light protein (NFL) levels were measured in paired plasma and CSF samples. Pretreatment samples were available for 14 patients. Cognitive function was assessed by CogState at follow-up. RESULTS: CSF neopterin decreased from a median (IQR) of 17.8 (10.6-29.7) to 6.1 (4.6-8.0) nmol/l during treatment (P < 0.001). In 11 out of 20 participants (55%), CSF neopterin levels were above the upper normal reference limit (5.8 nmol/l) at follow-up. Age-adjusted CSF NFL decreased to within-normal levels from a median of (IQR) 1179 (557-2707) to 415 (292-610) ng/l (P < 0.001). No significant correlations were found between CSF neopterin and CSF NFL or neurocognitive performance. CONCLUSION: Although CSF neopterin decreased significantly, more than 50% of the patients had CSF concentrations above the upper normal reference value despite more than 10 years of suppressive ART. We found no correlation between CSF neopterin, CSF NFL or neurocognitive performance at follow-up, indicating that low-grade immune activation during suppressive ART may be clinically benign.
Authors: Isaac H Solomon; Sukrutha Chettimada; Vikas Misra; David R Lorenz; Robert J Gorelick; Benjamin B Gelman; Susan Morgello; Dana Gabuzda Journal: Mol Neurobiol Date: 2019-11-05 Impact factor: 5.590
Authors: Joanna Hellmuth; Bonnie M Slike; Carlo Sacdalan; John Best; Eugene Kroon; Nittaya Phanuphak; James L K Fletcher; Peeriya Prueksakaew; Linda L Jagodzinski; Victor Valcour; Merlin Robb; Jintanat Ananworanich; Isabel E Allen; Shelly J Krebs; Serena Spudich Journal: J Infect Dis Date: 2019-11-06 Impact factor: 5.226
Authors: Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: Albert M Anderson; Jeong Hoon Jang; Kirk A Easley; Dietmar Fuchs; Magnus Gisslen; Henrik Zetterberg; Kaj Blennow; Ronald J Ellis; Donald Franklin; Robert K Heaton; Igor Grant; Scott L Letendre Journal: J Acquir Immune Defic Syndr Date: 2020-12-15 Impact factor: 3.731
Authors: Beret Amundson; Lillin Lai; Mark J Mulligan; Yong Xu; Zidou Zheng; Suprateek Kundu; Jeffrey L Lennox; Drenna Waldrop-Valverde; Donald Franklin; Alison Swaims-Kohlmeier; Scott L Letendre; Albert M Anderson Journal: J Neuroimmunol Date: 2020-04-27 Impact factor: 3.478